A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E8001 in Healthy Male Subjects
Latest Information Update: 27 Sep 2023
At a glance
- Drugs E 8001 (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Co Ltd
- 22 Sep 2023 Status changed from active, no longer recruiting to completed.
- 29 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.